UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000053234
Receipt number R000060752
Scientific Title Short-term weight loss and body composition changes in patients with obesity by GLP-1 and GIP/GLP-1 receptor agonists in combination with low-calorie diet.
Date of disclosure of the study information 2023/12/31
Last modified on 2023/12/30 16:07:28

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Short-term weight loss and body composition changes in patients with obesity by GLP-1 and GIP/GLP-1 receptor agonists in combination with low-calorie diet.

Acronym

Short-term therapeutic effects of GLP-1 and GIP/GLP-1 receptor agonists on patients with obesity during severe energy restriction.

Scientific Title

Short-term weight loss and body composition changes in patients with obesity by GLP-1 and GIP/GLP-1 receptor agonists in combination with low-calorie diet.

Scientific Title:Acronym

Short-term therapeutic effects of GLP-1 and GIP/GLP-1 receptor agonists on patients with obesity during severe energy restriction.

Region

Japan


Condition

Condition

obesity

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the short-term effects of GLP-1 and GIP/GLP-1 receptor agonists on weight and body composition changes in patients with obesity undergoing a low-calorie diet.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Percentage changes in body composition during inpatient treatment with low-calorie diet for thirteen days.

Key secondary outcomes

Percentage changes in body weight and body mass index, as well as systolic and diastolic blood pressure, fasting blood glucose, C-peptide, TG, HDL-C and LDL-C and subcutaneous and visceral fat area during inpatient treatment with low-calorie diet for thirteen days.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) Patients with BMI of 25 kg/m2 or higher aged 18 years or older in Japan.
(2) Patients who admitted to our hospital for weight loss between January 2019 and December 2023 and completed a 13 days low-calorie-diet therapy (LCD) provided by our hospital to replace their three daily meals.
(3) Patients who had started using oral or subcutaneous semaglutide or tirzepatide within 8 weeks prior to and 1 week after admission, or those with no history of GLP-1 receptor agonist use

Key exclusion criteria

(1) Patients who were or plan to be pregnant.
(2) Patients who were unable to cooperate with treatment due to mental illness or language barrier.
(3) Patients with a history of GLP-1 receptor agonist use other than oral and subcutaneous semaglutide and tirzepatide.
(4) Patients who failed to continue GLP-1 or GIP/GLP-1 receptor agonists during hospitalization.
(5) Patients who were unable to continue the LCD provided by our hospital.
(6) Other patients deemed inappropriate as research subjects by the principal investigator.

Target sample size

40


Research contact person

Name of lead principal investigator

1st name Ryoichi
Middle name
Last name Ishibashi

Organization

Kimitsu Chuo Hospital

Division name

Department of Medicine, Division of Diabetes, Endocrinology and Metabolism

Zip code

292-8535

Address

1010 Sakurai, Kisarazu-city, Chiba

TEL

0438-36-1071

Email

ishibashi-cib@umin.net


Public contact

Name of contact person

1st name Ryoichi
Middle name
Last name Ishibashi

Organization

Kimitsu Chuo Hospital

Division name

epartment of Medicine, Division of Diabetes, Endocrinology and Metabolism

Zip code

292-8535

Address

1010 Sakurai, Kisarazu-city, Chiba

TEL

0438-36-1071

Homepage URL


Email

ishibashi-cib@umin.net


Sponsor or person

Institute

Kimitsu Chuo Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kimitsu Chuo Hospital

Address

1010 Sakurai, Kisarazu-city, Chiba

Tel

0438-36-1071

Email

ishibashi-cib@umin.net


Secondary IDs

Secondary IDs

YES

Study ID_1

752

Org. issuing International ID_1

Kimitsu Chuo Hospital

Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 12 Month 31 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2023 Year 11 Month 30 Day

Date of IRB


Anticipated trial start date

2023 Year 11 Month 30 Day

Last follow-up date

2024 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

The present observational study investigated the short-term effects of semaglutide and tirzepatide on weight loss and body composition in people with obesity under severe calorie restriction.


Management information

Registered date

2023 Year 12 Month 26 Day

Last modified on

2023 Year 12 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000060752


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name